関連する実験動画

Updated: May 5, 2026

Three-dimensional Navigation-guided, Prone, Single-position, Lateral Lumbar Interbody Fusion Technique
08:38

Three-dimensional Navigation-guided, Prone, Single-position, Lateral Lumbar Interbody Fusion Technique

Published on: July 15, 2021

3.8K

GLP-1受容体アゴニストの使用とACDF後の術後の結果:傾向を合わせたコホート研究

Kevin Y Heo1, Stephen R Barchick1, Aubrie M Sowa1

  • 1Department of Orthopaedic Surgery, Emory University School of Medicine, 21 Ortho Ln, Atlanta, Georgia, 30329.

The spine journal : official journal of the North American Spine Society
|January 2, 2026
PubMed
まとめ

No abstract available in PubMed .

キーワード:
前部子宮頸椎切除と合併GLP-1受容体アゴニストグルカゴン類ペプチド-1受容体アゴニスト肥満手術後の合併症手術後の合併症2 型糖尿病

さらに関連する動画

Clinical Application of Microscope-Assisted Minimally Invasive Anterior Lumbar Interbody Fusion04:42

Clinical Application of Microscope-Assisted Minimally Invasive Anterior Lumbar Interbody Fusion

Published on: June 16, 2023

925
Multilevel Oblique Lumbar Interbody Fusion in Degenerative Lumbar Disc Disease with Instability11:30

Multilevel Oblique Lumbar Interbody Fusion in Degenerative Lumbar Disc Disease with Instability

Published on: July 25, 2025

1.0K

関連する概念動画

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K